Table 2 Hazard ratios of major adverse cardiovascular events (MACEs) associated with exposure to various antidiabetic drugs
MACEs | Time at risk (person-years) | Incidence rate (per 1000 person-years) | Unadjusted HR (95Â % CI) | Adjusted HR* (95Â % CI) | p value |
|---|---|---|---|---|---|
DPP4i | 28,508 | 39.56 | 0.82 | 0.83 (0.76, 0.91) | <0.0001 |
(ref.=non-DPP4i users) | 334,148 | 41.53 | – | – | – |
Sulfonylureas | 110,618 | 35.99 | 0.67 | 0.80 (0.77, 0.84) | <0.0001 |
(ref. = non-sulfonylureas users) | 252,038 | 43.74 | – | – | – |
Acarbose | 22,800 | 48.37 | 1.01 | 0.92 (0.85, 0.99) | 0.0463 |
(ref. = non-acarbose users) | 339,856 | 26.10 | – | – | – |
Meglitinides | 13,103 | 102.49 | 2.23 | 1.46 (1.35, 1.58) | <0.0001 |
(ref. = non-meglitinide users) | 349,553 | 39.08 | – | – | – |
Insulin | 9632 | 206.06 | 4.75 | 3.53 (3.23, 3.87) | <0.0001 |
(ref. = non-insulin users) | 353,024 | 36.88 | – | – | – |
Metformin | 172,813 | 30.87 | 0.48 | 0.66 (0.63, 0.69) | <0.0001 |
(ref. = non-metformin users) | 189,843 | 45.00 | – | – | – |
Pioglitazone | 4678 | 24.15 | 0.49 | 0.61 (0.50, 0.75) | <0.0001 |
(ref. = non-pioglitazone users) | 357,978 | 41.60 | – | – | – |
Rosiglitazone | 504 | 35.64 | 0.69 | 0.78 (0.49, 1.26) | 0.3187 |
(ref. = non-rosiglitazone users) | 362,152 | 41.38 | – | – | – |